4-[2-(8-tert-butyl-3-oxo-2-piperidin-1-yl-1,4-diazaspiro[4.5]dec-1-en-4-yl)ethyl]-N-ethylbenzamide
C28H42N4O2 — CID 71202212
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[2-(8-tert-butyl-3-oxo-2-piperidin-1-yl-1,4-diazaspiro[4.5]dec-1-en-4-yl)ethyl]-N-ethylbenzamide
4-[2-(8-tert-butyl-3-oxo-2-piperidin-1-yl-1,4-diazaspiro[4.5]dec-1-en-4-yl)ethyl]-N-ethylbenzamide (PubChem CID 71202212) has the molecular formula C28H42N4O2 and a molecular weight of 466.67 g/mol. Its IUPAC name is 4-[2-(8-tert-butyl-3-oxo-2-piperidin-1-yl-1,4-diazaspiro[4.5]dec-1-en-4-yl)ethyl]-N-ethylbenzamide.
Molecular Properties
| Compound Name | 4-[2-(8-tert-butyl-3-oxo-2-piperidin-1-yl-1,4-diazaspiro[4.5]dec-1-en-4-yl)ethyl]-N-ethylbenzamide |
|---|---|
| PubChem CID | 71202212 |
| Molecular Formula | C28H42N4O2 |
| Molecular Weight | 466.67 g/mol |
| Exact Mass | 466.33 |
| IUPAC Name | 4-[2-(8-tert-butyl-3-oxo-2-piperidin-1-yl-1,4-diazaspiro[4.5]dec-1-en-4-yl)ethyl]-N-ethylbenzamide |
| SMILES | CCNC(=O)c1ccc(CCN2C(=O)C(N3CCCCC3)=NC23CCC(C(C)(C)C)CC3)cc1 |
| InChI | InChI=1S/C28H42N4O2/c1-5-29-25(33)22-11-9-21(10-12-22)15-20-32-26(34)24(31-18-7-6-8-19-31)30-28(32)16-13-23(14-17-28)27(2,3)4/h9-12,23H,5-8,13-20H2,1-4H3,(H,29,33) |
| InChIKey | GGCXRTAFMPNOAN-UHFFFAOYSA-N |
| XLogP | 4.64 |
| TPSA | 65.01 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 466.67 |
| LogP ≤ 5 | 4.64 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 71202212 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.